Zhengzhou, China – January 28, 2013, Zhengzhou Granlen PharmaTech Ltd, a Division of Granlen LLC in San Diego, California, USA, announced today it has accomplished the full scale preclinical studies together with collaborators for the submission of an Investigational New Drug (IND) to China State Food and Drug Administration (SFDA) for clinical study approval of Azvudine, a nucleoside reverse-transcriptase inhibitor. Granlen has successfully passed the official on-site auditing process on Azvudine, its CMC, stability, and related.

“We are extremely pleased for this IND submission. With this accomplishment, Granlen has trained team and established facility as well as the regulated documentation very well to face great challenges and meet our global clients’ need,” said Harry An, Ph. D., Founder and President, Granlen. “We will continue to work closely with our partners and regulatory authorities to bring this important new therapy to human, and to support its subsequent and further clinical studies.”

About Granlen – “The Reliability”

Granlen is a global contract research organization (CRO) to provide reliable chemistry, drug discovery and development related services for biotech, pharmaceutical, cosmaceutical, and related industries with a broad spectrum of chemistry, a wide range of drug discovery services, and an integrated drug development process to IND. The highly experienced team in multidisciplinary areas is committed to exceeding clients’ expectations and becoming your partner of choice. Therefore, Granlen is cable of providing high quality, reliable and cost-effective chemistry-driven drug discovery and development services.

Forward-Looking Statement

This press release may contain forward-looking statements that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Granlen, and Granlen assumes no obligation to update any such forward-looking statements.

For more information on Granlen, please visit the company’s website at www.granlen.com or send inquiry to info@granlen.com, or contact:

philip.fang, philip.fang@granlen.com; +86-371-85513397

Zhengzhou Granlen PharmaTech Ltd., a Division of Granlen